文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

代谢综合征与急性呼吸窘迫综合征患者死亡率的关系:ARDS Network与PETAL Network试验分析

The Relationship Between Metabolic Syndrome and Mortality Among Patients With Acute Respiratory Distress Syndrome in Acute Respiratory Distress Syndrome Network and Prevention and Early Treatment of Acute Lung Injury Network Trials.
PubMed 文献 · Crit Care Med · 2023-11-01
一句话结论在非COVID-19的ARDS患者中,合并代谢综合征(肥胖、糖尿病、高血压)与28天和90天死亡率降低相关(aOR 0.70和0.75),感染性病因亚组更明显。

该研究为对ARDS Network和PETAL Network七项随机试验数据的回顾性队列分析,纳入4288例住院ARDS患者,其中454例(10.6%)符合代谢综合征标准(肥胖、糖尿病、高血压中至少三项),与3834例对照(不足三项)比较。主要终点28天死亡率在代谢综合征组更低(aOR 0.70,95%CI 0.55-0.89),90天死亡率亦低(aOR 0.75,95%CI 0.60-0.95)。代谢指标每增加一项,校正28天死亡率分别降低18%、22%和40%。亚组分析显示,在脓毒症或肺炎所致ARDS中死亡率降低(28天aOR 0.64,90天aOR 0.69),而非感染性病因中无显著差异(28天aOR 1.18,90天aOR 1.26),交互作用P=0.04和P=0.02。提示代谢炎症与ARDS的关系可能为精准医学试验提供新方向。

要点

  • 在非COVID-19的ARDS试验人群中,合并代谢综合征(肥胖、糖尿病、高血压)与28天死亡率降低独立相关(aOR 0.70,95%CI 0.55-0.89)。
  • 90天死亡率同样降低(aOR 0.75,95%CI 0.60-0.95),代谢指标每增加一项,28天死亡率分别降低18%、22%、40%。
  • 亚组分析:脓毒症或肺炎所致ARDS中代谢综合征组死亡率更低(28天aOR 0.64,90天aOR 0.69),非感染性病因中无显著差异(28天aOR 1.18,90天aOR 1.26)。
  • 代谢综合征与ARDS病因的交互作用显著(28天P=0.04,90天P=0.02),提示代谢炎症可能为精准医学提供新靶点。

适用人群与场景

  • 住院的ARDS患者,数据来自ARDS Network和PETAL Network的七项随机试验,纳入Biologic Specimen and Data Repository Information Coordinating Center数据库。
  • 代谢综合征定义为肥胖、糖尿病和高血压中至少三项;对照组为不足三项者。

诊断标准与关键阈值

  • 代谢综合征定义:肥胖、糖尿病、高血压中至少满足三项。

研究设计与关键结果

  • 研究类型:对七项ARDS Network和PETAL Network随机试验数据的回顾性队列分析;样本量4288例,代谢综合征组454例(10.6%),对照组3834例(89.4%)。
  • 主要终点28天死亡率:代谢综合征组 vs 对照组校正比值比(aOR)0.70(95%CI 0.55-0.89)。
  • 90天死亡率:代谢综合征组 vs 对照组aOR 0.75(95%CI 0.60-0.95)。
  • 代谢指标从0增至3项,校正28天死亡率分别降低18%、22%和40%。
  • 亚组分析:脓毒症或肺炎所致ARDS中,代谢综合征组 vs 对照组28天aOR 0.64(95%CI 0.48-0.84),90天aOR 0.69(95%CI 0.53-0.89);非感染性病因中28天aOR 1.18(95%CI 0.70-1.99),90天aOR 1.26(95%CI 0.77-2.06)。
  • 交互作用P值:28天比较P=0.04,90天比较P=0.02。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(对随机试验数据的二次分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在非COVID-19的ARDS患者中,合并代谢综合征(肥胖、糖尿病、高血压)可能提示较低的死亡风险,尤其当ARDS病因为脓毒症或肺炎时;但该关联来自回顾性分析,作者认为代谢炎症与ARDS的关系可能为精准医学试验提供新生物学途径。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Metabolic syndrome is known to predict outcomes in COVID-19 acute respiratory distress syndrome (ARDS) but has never been studied in non-COVID-19 ARDS. We therefore aimed to determine the association of metabolic syndrome with mortality among ARDS trial subjects.

DESIGN: Retrospective cohort study of ARDS trials' data.

SETTING: An ancillary analysis was conducted using data from seven ARDS Network and Prevention and Early Treatment of Acute Lung Injury Network randomized trials within the Biologic Specimen and Data Repository Information Coordinating Center database.

PATIENTS: Hospitalized patients with ARDS and metabolic syndrome (defined by obesity, diabetes, and hypertension) were compared with similar patients without metabolic syndrome (those with less than three criteria).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was 28-day mortality. Among 4288 ARDS trial participants, 454 (10.6%) with metabolic syndrome were compared with 3834 controls (89.4%). In adjusted analyses, the metabolic syndrome group was associated with lower 28-day and 90-day mortality when compared with control (adjusted odds ratio [aOR], 0.70 [95% CI, 0.55-0.89] and 0.75 [95% CI, 0.60-0.95], respectively). With each additional metabolic criterion from 0 to 3, adjusted 28-day mortality was reduced by 18%, 22%, and 40%, respectively. In subgroup analyses stratifying by ARDS etiology, mortality was lower for metabolic syndrome vs. control in ARDS caused by sepsis or pneumonia (at 28 d, aOR 0.64 [95% CI, 0.48-0.84] and 90 d, aOR 0.69 [95% CI, 0.53-0.89]), but not in ARDS from noninfectious causes (at 28 d, aOR 1.18 [95% CI, 0.70-1.99] and 90 d, aOR 1.26 [95% CI, 0.77-2.06]). Interaction p = 0.04 and p = 0.02 for 28- and 90-day comparisons, respectively.

CONCLUSIONS: Metabolic syndrome in ARDS was associated with a lower risk of mortality in non-COVID-19 ARDS. The relationship between metabolic inflammation and ARDS may provide a novel biological pathway to be explored in precision medicine-based trials.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Tea K, Zu Y, Chung CH, et al. The Relationship Between Metabolic Syndrome and Mortality Among Patients With Acute Respiratory Distress Syndrome in Acute Respiratory Distress Syndrome Network and Prevention and Early Treatment of Acute Lung Injury Network Trials. Crit Care Med. 2023. PMID: 37909824. doi:10.1097/CCM.0000000000006092

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。